ATE487723T1 - Substituierte furoä2,3-büpyridinderivate als cannabinoid-1-rezeptormodulatoren - Google Patents

Substituierte furoä2,3-büpyridinderivate als cannabinoid-1-rezeptormodulatoren

Info

Publication number
ATE487723T1
ATE487723T1 AT08742647T AT08742647T ATE487723T1 AT E487723 T1 ATE487723 T1 AT E487723T1 AT 08742647 T AT08742647 T AT 08742647T AT 08742647 T AT08742647 T AT 08742647T AT E487723 T1 ATE487723 T1 AT E487723T1
Authority
AT
Austria
Prior art keywords
furoä2
bupyridine
cannabinoid
derivatives
substituted
Prior art date
Application number
AT08742647T
Other languages
English (en)
Inventor
Matthew Clements
John Debenham
Jeffrey Hale
Christina Madsen-Duggan
Thomas Walsh
Andrey Peresypkin
Roy Helmy
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE487723T1 publication Critical patent/ATE487723T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT08742647T 2007-04-11 2008-04-07 Substituierte furoä2,3-büpyridinderivate als cannabinoid-1-rezeptormodulatoren ATE487723T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92285107P 2007-04-11 2007-04-11
PCT/US2008/004533 WO2008127585A1 (en) 2007-04-11 2008-04-07 Substituted furo[2,3-b]pyridine derivatives as cannabinoid-1 receptor modulators

Publications (1)

Publication Number Publication Date
ATE487723T1 true ATE487723T1 (de) 2010-11-15

Family

ID=39473766

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08742647T ATE487723T1 (de) 2007-04-11 2008-04-07 Substituierte furoä2,3-büpyridinderivate als cannabinoid-1-rezeptormodulatoren

Country Status (12)

Country Link
US (1) US20080269279A1 (de)
EP (1) EP2146997B1 (de)
JP (1) JP2010523665A (de)
AR (1) AR065983A1 (de)
AT (1) ATE487723T1 (de)
AU (1) AU2008239755A1 (de)
CA (1) CA2683586A1 (de)
CL (1) CL2008001007A1 (de)
DE (1) DE602008003432D1 (de)
PE (1) PE20090142A1 (de)
TW (1) TW200906398A (de)
WO (1) WO2008127585A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8324239B2 (en) 2010-04-21 2012-12-04 Novartis Ag Furopyridine compounds and uses thereof
WO2011137012A1 (en) * 2010-04-27 2011-11-03 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
PL3360860T3 (pl) * 2015-10-09 2022-09-26 Mitsui Chemicals Agro, Inc. Związek pirydonowy i rolnicze/ogrodnicze bakteriocydy, w których stanowi on składnik aktywny
BR112023002497A2 (pt) * 2020-08-12 2023-05-02 Spruce Biosciences Inc Métodos e composições para tratamento da síndrome dos ovários policísticos

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1454864A (en) * 1974-03-05 1976-11-03 Wyeth John & Brother Ltd Thioureas
US4973587A (en) * 1990-03-08 1990-11-27 Sterling Drug Inc. 3-arylcarbonyl-1-aminoalkyl-1H-indole-containing antiglaucoma method
US5013837A (en) * 1990-03-08 1991-05-07 Sterling Drug Inc. 3-Arylcarbonyl-1H-indole-containing compounds
US5338740A (en) * 1993-07-13 1994-08-16 Pfizer Inc. Angiotensin II receptor antagonists
US5489685A (en) * 1994-05-12 1996-02-06 Merck & Co., Ltd. Method of synthesizing furo[2,3-b]pyridine carboxylic acid esters
US5596106A (en) * 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
US5656638A (en) * 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5703116A (en) * 1995-04-18 1997-12-30 Geron Corporation Telomerase Inhibitors
FR2741621B1 (fr) * 1995-11-23 1998-02-13 Sanofi Sa Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
FR2758723B1 (fr) * 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
US7774473B2 (en) * 2002-07-31 2010-08-10 Oracle America, Inc. System and method for sticky routing of requests within a server farm
JP4667867B2 (ja) * 2002-08-02 2011-04-13 メルク・シャープ・エンド・ドーム・コーポレイション 置換フロ［２，３−ｂ］ピリジン誘導体
US7329658B2 (en) * 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) * 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US20040214856A1 (en) * 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) * 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) * 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) * 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
TW200602314A (en) * 2004-05-28 2006-01-16 Tanabe Seiyaku Co A novel pyrrolidine compound and a process for preparing the same
US7674907B2 (en) * 2004-07-23 2010-03-09 Amgen Inc. Furanopyridine derivatives and methods of use

Also Published As

Publication number Publication date
EP2146997A1 (de) 2010-01-27
JP2010523665A (ja) 2010-07-15
AU2008239755A1 (en) 2008-10-23
CA2683586A1 (en) 2008-10-23
US20080269279A1 (en) 2008-10-30
DE602008003432D1 (de) 2010-12-23
CL2008001007A1 (es) 2008-10-17
TW200906398A (en) 2009-02-16
PE20090142A1 (es) 2009-02-19
EP2146997B1 (de) 2010-11-10
AU2008239755A8 (en) 2009-11-12
AR065983A1 (es) 2009-07-15
WO2008127585A1 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
DK2144897T3 (da) 8-Oxy-quinolinderivater som bradykinin B2-receptormodulatorer
ATE537157T1 (de) Substituierte phenoxy-n-alkylierte thiazoledindione als östrogenassoziierte rezeptor-alpha-modulatoren
ATE502938T1 (de) Pyridinderivate als s1p1/edg1-rezeptormodulatoren
DK2176220T3 (da) Pyrrolidin-2-on-derivater som androgenreceptormodulatorer.
ATE509022T1 (de) Nikotin-acetylcholin-rezeptorsubtyp-selektive diazabicycloalkanamide
DE602007006531D1 (de) Pyrazin-2-carboxamid-derivate als cb2-rezeptormodulatoren
ATE555107T1 (de) 2-aza-bicyclo-ä2,2,1-üheptan-derivate
DK2952177T3 (da) Sammensætninger, der omfatter sphingosin-1-phosphat (s1p)-receptormodulatorer
BRPI0813707A2 (pt) Derivados de pirimidinil-piridazinona
BRPI0820112A2 (pt) Derivados de isoxazol-piridina
BRPI0809992A2 (pt) Derivados de pirrolopirimidina
BRPI0820113A2 (pt) Derivados de isoxazolo-piridazina
BRPI0812155A2 (pt) derivados de espiroindolinona
BRPI0817935A2 (pt) Derivados de biarila
DK2094658T3 (da) Tetrahydrocyclopenta[B]indolforbindelser som androgenreceptormodulatorer
BRPI0812518A2 (pt) Derivados de indazolamida
BRPI0814236A2 (pt) Derivados de quinazolinamida
BR112012008159A2 (pt) moduladores de receptor canabinoide
BRPI0820649A2 (pt) Derivados de isoxazalo-pirazina
DK2297100T3 (da) Tetrahydrocyclopenta[b]indol-androgenreceptor-modulatorer
DK2344471T3 (da) 7-piperidinalkyl-3,4-dihydroquinolon-derivat
BRPI0919898A2 (pt) 4,5,6,7-tetra-hidrotienopiridinas substituídas como moduladores de kcnq2/3
BRPI0820805A2 (pt) Antagonista do receptor de mineralocorticóides derivados da 6h-di-benzo[b,e]oxepina
BRPI0917446A2 (pt) derivados de acilaminobenzamida.
ATE527260T1 (de) (dihydro)pyrroloä2,1-aüisoquinoline

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties